Outlook Therapeutics Q2 FY2026 net loss narrows to $4.5M; FDA decision on ONS-5010 expected May 2026

Outlook Therapeutics, Inc.

2026-Q2 EPS reported -$0.39

Net loss of $4.5M ($0.05/sh) vs $46.4M ($1.50/sh) YoY; adjusted net loss $14.1M ($0.16/sh).
LYTENAVA unit sales in Europe down ~10% QoQ; cost reduction steps initiated to improve margins.
Cash $7.7M as of Mar 31; raised ~$4M in March offering and $4.2M net in April registered direct offering.
FDA formal dispute resolution meeting completed in April; written decision expected within May 2026.
Entered Swiss distribution agreement with Mediconsult AG; targeting 2027 launch pending marketing authorization.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.